Latest News

Regeneron developing antibodies to target omicron as current cocktail loses potency against variant


CEO Leonard Schleifer told CNBC Regeneron plans to conduct trials on the new antibodies in the first quarter of 2022.

H&R Block sues over Square’s new name ‘Block’

Previous article

How bad is inflation? Even millionaires are worried about it.

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News